Every DEF 14A that Creative Medical Technology Holdings, Inc. (CELZ) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CELZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CELZ filings page.
Creative Medical Technology Holdings, Inc. is calling a special stockholder meeting on August 28, 2026 to vote on two capital-structure proposals. The first would amend its Articles of Incorporation to increase authorized common stock from 25,000,000 to 100,000,000 shares, giving flexibility for future capital raising, equity incentives, strategic relationships, or acquisitions, while acknowledging potential dilution and anti-takeover effects.
The second proposal seeks approval for the exercise in full of private-placement Investor Warrants to purchase 5,580,680 shares of common stock at $1.60 per share. Because exercising these warrants would issue more than 20% of currently outstanding shares, Nasdaq Listing Rule 5635(d) requires stockholder approval, and company agreements obligate repeated meetings every 60 days until approval is obtained. As of June 30, 2026, common shares outstanding were 4,741,236, with warrants and options for an additional 10,633,425 shares.
Creative Medical Technology Holdings (CELZ) called a special meeting to approve, for purposes of Nasdaq Listing Rule 5635(d), the exercise in full of inducement warrants covering 2,790,340 shares of common stock at an exercise price of $2.86 per share. The warrants, issued on October 29, 2025 in a private placement, are not exercisable until stockholders approve this proposal and would then be exercisable for five years following approval.
The board unanimously recommends a vote FOR. The company notes that approval could lead to dilution for existing stockholders and that subsequent sales of shares issued upon exercise could pressure the stock price. If the proposal is not approved, the company must hold additional stockholder meetings every 90 days until approval is obtained.
Creative Medical Technology Holdings (CELZ) called its 2025 Annual Meeting for December 18, 2025 at 9:00 a.m. PST in Solana Beach, CA. Stockholders will vote on three items: electing five directors, an advisory say‑on‑pay for named executive officers, and ratifying Haynie & Company as independent auditor for the year ending December 31, 2025.
The Board set October 27, 2025 as the record date, with 2,579,930 shares of common stock outstanding on that date. Directors are elected by a plurality of votes cast; the say‑on‑pay and auditor ratification require a majority of shares present and entitled to vote. The Board unanimously recommends FOR all three proposals.
The company reports three independent directors on its five‑member Board and standard committee structures. For 2024, audit fees to Haynie & Company were $92,772. The proxy also outlines executive and director compensation, equity plans, and related‑party policies to guide governance and compliance.